POS0935 DO PERIPHERAL AND EXTRA MUSCULOSKELETAL MANIFESTATIONS HAVE AN IMPACT ON BIOLOGIC DMARD PRESCRIBING PATTERNS IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF TREASURE EXPERIENCE

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis enthesitis may also occur. Extra musculoskeletal manifestations (EMMs; uveitis [AAU], bowel [IBD] psoriasis [Pso] are among the most common ones) important features might have an impact on burden in patients with axSpA. The presence of EMM, particular IBD AAU could influence choice TNFi however little known regarding role peripheral together EMM prescribing patterns axSpA patients. Objectives: To examine frequency EMMs real-world cohort their effect first advanced treatment. Methods: In total 1687 (58% male mean age (±SD) was 38.5 ± 10.9) who initiated his/her biologic were included present analysis. data for current study obtained from TReasure web-based registry; which RA SpA treated bDMARDs different regions Turkey. Baseline demographic, related characteristics, extracted. Characteristics without peripheral/extra-musculoskelatal involvement compared as well factors/covariates associated secukinumab analysed. Results: Enthesis (28.2%) found arthritis (26.4%) hip (24.4%) followed it. Symptom duration to treatment initiation significantly shorter enthesitis, longer AAU. HLA-B27 positivity lower higher multivariate analysis preference monoclonal (mab) over etanercept (ETA) (OR 5,770; 95%CI 1.788-18.616). However ETA preferred ( p =0.003), symptom =0.049), using sulfasalazine =0.043). comparison mabs, (SEC) prescription be =0.001), sulfasalazin =0.001) methotrexate usage =0.053) need Conclusion: results confirm pathophsyologic associations Apart has real-life. Table 1. Clinical characteristics All (n=1678) (n=445) Dactilitis (n=81) (n=476) Uveitis (n=193) Psoriazis (n=152) IBD(n=78) Hip involvemet(n=412) Age, mean±SD 38,5±10,9 38,3±11,6 37,4±11,1 37,9±10,7 41,3±11,4 39,9±11,3 41,6±12,2 39,2±11,2 Male sex,n (%) 974 (57,7) 184 (41,3) 34 (42) 238 (50) 96 (49,7) 54 (35,5) 43 (55,1) 272 (66) duration, month±SD 108,5±98,9 96,9±92,9 79,1±76,5 100,4±92,7 144,7±110,2 87,7±94 94,5±98 133,3±108,2 HLA B27 positivity, n 621 (53,7) 142 (46,3) 27 (51,9) 174 (49,4) 104 (77) (36,2) 16 (27,1) 186 (59,8) Concomitant cDMARD (yes), 420 (24,9) 170 (38,2) 39 (48,1) 133 (27,9) 53 (27,5) 58 24 (30,8) 99 (24) BASDAİ, 5,1±2,5 5,1±3 5,3±3,1 5,3±2,9 4,7±2,5 5,6±2,4 4,8±2,3 5,3±2,1 ASDAS-CRP, 3,1±1,5 2,6±1,9 2,5±1,8 2,8±1,7 2,9±1,7 3,4±1,3 3,7±1,4 Disclosure Interests: None declared